Follow
Jyothis Thomas George MBBS, PhD, FACE, FRCP
Jyothis Thomas George MBBS, PhD, FACE, FRCP
Vice President & Global TA Head for Cardiovascular & Metabolism
Verified email at amgen.com - Homepage
Title
Cited by
Cited by
Year
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial
J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ...
Jama 321 (1), 69-79, 2019
11662019
How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
SE Inzucchi, B Zinman, D Fitchett, C Wanner, E Ferrannini, ...
Diabetes care 41 (2), 356-363, 2018
7122018
Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
C Wanner, JM Lachin, SE Inzucchi, D Fitchett, M Mattheus, J George, ...
Circulation 137 (2), 119-129, 2018
660*2018
Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial
J Rosenstock, SE Kahn, OE Johansen, B Zinman, MA Espeland, ...
Jama 322 (12), 1155-1166, 2019
6412019
The kisspeptin-GnRH pathway in human reproductive health and disease
K Skorupskaite, JT George, RA Anderson
Human reproduction update 20 (4), 485-500, 2014
5402014
Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial
D Fitchett, SE Inzucchi, CP Cannon, DK McGuire, BM Scirica, ...
Circulation 139 (11), 1384-1395, 2019
3382019
Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials
J Rosenstock, J Marquard, LM Laffel, D Neubacher, S Kaspers, ...
Diabetes care 41 (12), 2560-2569, 2018
3352018
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
D Fitchett, J Butler, P van de Borne, B Zinman, JM Lachin, C Wanner, ...
European heart journal 39 (5), 363-370, 2018
2742018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ...
Clinical kidney journal 11 (6), 749-761, 2018
2572018
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved …
SD Anker, J Butler, GS Filippatos, W Jamal, A Salsali, J Schnee, K Kimura, ...
European journal of heart failure 21 (10), 1279-1287, 2019
2442019
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
JT George, JD Veldhuis, AK Roseweir, CL Newton, E Faccenda, RP Millar, ...
The Journal of Clinical Endocrinology & Metabolism 96 (8), E1228-E1236, 2011
2112011
Physiology of GNRH and gonadotropin secretion
P Marques, K Skorupskaite, KS Rozario, RA Anderson, JT George
Endotext [internet], 2022
1932022
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors
J Butler, CE Hamo, G Filippatos, SJ Pocock, RA Bernstein, M Brueckmann, ...
European journal of heart failure 19 (11), 1390-1400, 2017
1882017
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG …
N Sattar, D Fitchett, S Hantel, JT George, B Zinman
Diabetologia 61, 2155-2163, 2018
1802018
Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications
J Young, JT George, JA Tello, B Francou, J Bouligand, ...
Neuroendocrinology 97 (2), 193-202, 2013
1762013
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME
S Verma, CD Mazer, M Al-Omran, SE Inzucchi, D Fitchett, U Hehnke, ...
Circulation 137 (4), 405-407, 2018
1742018
Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA
DK McGuire, JH Alexander, OE Johansen, V Perkovic, J Rosenstock, ...
Circulation 139 (3), 351-361, 2019
1722019
Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control
SE Inzucchi, M Kosiborod, D Fitchett, C Wanner, U Hehnke, S Kaspers, ...
Circulation 138 (17), 1904-1907, 2018
1662018
Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease―results from EMPA-REG OUTCOME®―
K Kaku, J Lee, M Mattheus, S Kaspers, J George, HJ Woerle, ...
Circulation journal 81 (2), 227-234, 2017
1492017
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced …
M Packer, J Butler, GS Filippatos, W Jamal, A Salsali, J Schnee, K Kimura, ...
European journal of heart failure 21 (10), 1270-1278, 2019
1422019
The system can't perform the operation now. Try again later.
Articles 1–20